The Sundyota Numandis Group, on Wednesday, announced a strategic alliance with Finzelberg, Germany, to offer novel, natural healthcare products in India.

To start with, Sundyota Numandis will introduce ERr731, a product complementing women’s health during menopause and pre-menopause.

Sundyota Numandis is a global health-oriented organisation focused on providing safe healthcare products and clinically proven therapies from non-synthetic sources.

Finzelberg is a business unit of the Martin Bauer Group (Germany), manufacturing phyto-pharmaceuticals and phyto-nutraceuticals. The Martin Bauer Group is a supplier of herbal and fruit infusions, medicinal teas, flavoured black and green teas, aromas, herbal powders, botanicals, herbal, fruit and tea extracts. As part of the pact, Sundyota Numandis will procure active ingredients from Finzelberg, undertake their formulation and development and seek registration and regulatory approvals for the same. This will be followed by commercial manufacturing along with product launch, marketing and co-marketing through promotion to doctors and pharmaceutical companies in India, said Dinesh Kumar Arora, Managing Director-CEO, Sundyota Numandis.

The new product, unveiled here, aims to ease over 20 symptoms related to menopause and pre-menopause, thus acting as a natural female hormone. Being devoid of any side-effects over long term use, it has a safety profile. “We now have 12 international alliances to foster healthcare the natural way along with over 60 patented therapies. ERr731 is safer than any currently available therapy for menopause. It facilitates a smooth transition for women experiencing menopause,” he said.

comment COMMENT NOW